The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, presents the initial analysis of the Phase III UNITY-CLL trial (NCT02612311), which assessed umbralisib with ublituximab in patients with chronic lymphocytic leukemia (CLL). Patients who have pre-existing comorbidities that exclude them from using Bruton’s tyrosine kinase inhibitors (BTKi) were enrolled and were given umbralisib with ublituximab, obinutuzumab with chlorambucil, umbralisib monotherapy, or ublituximab monotherapy. Existing comorbidities were not found to negatively impact the efficacy of umbralisib and ublituximab, providing an alternative treatment regimen for this subset of patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
